Gabriell Máté
Dr Gabriell Máté has a strong background in physics, computer science and mathematics. Following a PhD in theoretical biophysics and applied mathematics, he left academia to work as a pricing analyst and data scientist with a focus on the pharmaceutical industry. He joined Boehringer Ingelheim in 2016 as a lead data scientist where he developed impactful AI solutions to optimize market access and commercial performance of the company globally across a multitude of markets. He co-founded quantLab (UG), an award-winning AI company that strives to deliver industry-changing AI solutions for pharmaceutical companies. Gabriell joined Boston Consulting Group in October 2020.
Dr Gabriell Máté has a strong background in physics, computer science and mathematics. Following a PhD in theoretical biophysics and applied mathematics, he left academia to work as a pricing analyst and data scientist with a focus on the pharmaceutical industry.
He joined Boehringer Ingelheim in 2016 as a lead data scientist where he developed impactful AI solutions to optimize market access and commercial performance of the company globally across a multitude of markets.
He co-founded quantLab (UG), an award-winning AI company that strives to deliver industry-changing AI solutions for pharmaceutical companies.
Gabriell joined Boston Consulting Group in October 2020.
See more
He joined Boehringer Ingelheim in 2016 as a lead data scientist where he developed impactful AI solutions to optimize market access and commercial performance of the company globally across a multitude of markets.
He co-founded quantLab (UG), an award-winning AI company that strives to deliver industry-changing AI solutions for pharmaceutical companies.
Gabriell joined Boston Consulting Group in October 2020.
Articles: Gabriell Máté
Utilising Data-Science to Boost US Market Access in Volatile Times
USA / Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a wide range of patient groups, increasing access and driving down costs in the process. 2020 has been an exceptionally turbulent year – especially for the healthcare sector and the pharmaceutical…
Latest Report
